Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

B2B sales

- PMLiVE

Health leaders welcome EDPB’s opinion on adequacy of UK’s data protection standards

Opinion ‘paves way’ for sharing of health data between EU and the UK

- PMLiVE

bluebird bio anticipates lift of clinical holds on LentiGlobin in mid-2021

Previously reported case of MDS in phase 1/2 study has been re-classified as transfusion-dependent anaemia

- PMLiVE

WHO director-general says pandemic can be brought under control within months

World has tools to curb pandemic if applied ‘consistently and equitably’

- PMLiVE

NICE sets out plans for ‘ambitious’ five-year strategy

NICE refocuses on reducing health inequalities and accelerating access to the latest and most effective treatments

- PMLiVE

Janssen will not seek regulatory approval for Erleada plus Zytiga in prostate cancer

Decision follows mixed results from the phase 3 ACIS study

- PMLiVE

In sickness and in health

If prevention is better than cure, we will need to help it along

Oh no… not more training

Paul Hutchings, founder of fox&cat, discusses ways to help your team manage pressure in a more human, pressure-centric and engaging way

Fox&Cat

A magic milestone: Sally’s 10-year #LucidLife workiversary

Our people define our culture and there is no better example of what we are striving to achieve than what Sally Ratcliffe, Scientific Director, Lucid Group, has demonstrated over the...

Lucid Group Communications Limited

- PMLiVE

UK-based challenge study to re-expose healthy adults to COVID-19

Study will enrol participants aged 18-30 who have previously been infected with COVID-19

- PMLiVE

Italy accelerates the path towards digital therapeutics implementation

PME talks to Roberto Ascione, Gualberto Gussoni and Giuseppe Recchia about the advancement of digital therapeutics in Italy

Roche Basel Switzerland

Roche’s Ocrevus shows significant benefit in early-stage MS patients

The data was presented virtually at the American Academy of Neurology annual meeting

- PMLiVE

Second Sarclisa combination regimen for multiple myeloma approved in EU

Second indication for Sarclisa covers drug’s use in combination with another standard myeloma treatment

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links